Recent studies on CP therapy for COVID-19 have reported that CP with high levels of NAb titers from recovered patients with COVID-19 ameliorates clinical symptoms by decreasing viral load, while posing low risk of treatment183 and no significant transfusion-associated morbidity or mortality.184. Here, CP is linked to COVID-19.